A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

LESSONS LEARNED. The combination of axitinib and crizotinib has a manageable safety and tolerability profile, consistent with the profiles of the individual agents when administered as monotherapy. The antitumor activity reported here for the combination axitinib/crizotinib does not support further...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Michaelson, M. Dror, Gupta, Shilpa, Agarwal, Neeraj, Szmulewitz, Russell, Powles, Thomas, Pili, Roberto, Bruce, Justine Yang, Vaishampayan, Ulka, Larkin, James, Rosbrook, Brad, Wang, Erjian, Murphy, Danielle, Wang, Panpan, Lechuga, Maria Josè, Valota, Olga, Shepard, Dale R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738313/
https://ncbi.nlm.nih.gov/pubmed/31171735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0749
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados